Structure reports Phase 2b body-composition data and open-label extension results; no weight-loss plateau observed

Structure Therapeutics/Aleniglipron

Structure reported updated Phase 2b body-composition study data and open-label extension (OLE) results for aleniglipron. At 72 weeks, the 180 mg dose achieved 15.3% average weight loss and the 240 mg dose achieved 16.2% in continuing patients, with no plateau in weight loss, and favorable lean/fat body composition changes.

• 180 mg dose: 15.3% average weight loss at 72 weeks.
• 240 mg dose: 16.2% weight loss in patients continuing treatment.
• No evidence of weight-loss plateau; continued benefit at extended duration.
• Body composition analysis showed preferential fat loss over lean mass.
• Fewer than 5% of patients discontinued due to adverse events across all dose groups.